Theoretical Basis of Pathogenic Substance Removal During Plasmapheresis
Open Access
- 25 May 2011
- journal article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 15 (5) , 421-430
Abstract
This article explains theoretical considerations of prescribing plasmapheresis. It is important to consider several factors in prescribing apheresis: (i) the properties of pathogenic substances, such as molecular weight, distribution volume, compartment, and production rate; (ii) therapeutic conditions such as the processed plasma volume and the frequency of processing; and (iii) the patient's condition, such as active bleeding or infection. A substance's molecular weight determines whether it can be removed using a particular membrane filter. Substances with a small distribution volume and low production rate are removed. Consequently, the processed volume per total plasma volume is related to the single‐session efficacy. Nevertheless, even frequent therapy cannot reduce the total pool of a substance within the body if movement from outside the vessels is slow. Active bleeding or infection might be exacerbated by modalities other than simple plasma exchange with fresh plasma supplementation because such therapies cannot replenish substances other than albumin.Keywords
This publication has 24 references indexed in Scilit:
- Virus Removal and Eradication by Modified Double Filtration Plasmapheresis Decreases Factor XIII LevelsTherapeutic Apheresis and Dialysis, 2010
- A Patient Whose Factor XIII Level Was Decreased by Double Filtrate Plasmapheresis and Successfully Recovered by Infusion of Factor XIII ConcentrateTherapeutic Apheresis and Dialysis, 2010
- Complications of therapeutic plasma exchange: A prospective study of 1,727 proceduresJournal of Clinical Apheresis, 2007
- Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchangeJournal of Clinical Apheresis, 2007
- Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral loadHepatology Research, 2007
- Double Filtration Plasmapheresis Can Decrease Factor XIII ActivityTherapeutic Apheresis and Dialysis, 2007
- Complications of Therapeutic Plasma Exchange: Experience With 4857 TreatmentsTherapeutic Apheresis and Dialysis, 2005
- Factor XIII: Inherited and acquired deficiencyBlood Reviews, 1993
- Optimum Albumin Concentration of Supplementation Fluid for Double Filtration PlasmapheresisArtificial Organs, 1992
- Toward the Rational Prescription of Therapeutic Plasma Exchange: The Kinetics of Immunoglobulin RemovalSeminars in Dialysis, 1992